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Abstract: We have previously reported that Amadori compounds exert anti-diabetic 
effects by lowering sucrose-induced hyperglycemia in normal Sprague-Dawley rats. In the 
present study we extended our recent findings to evaluate whether α-glucosidase inhibitor 
arginyl-fructose (AF) lowers blood glucose level in diabetic db/db mice, a genetic model 
for type 2 diabetes. The db/db mice were randomly assigned to high-carbohydrate diets 
(66.1% corn starch) with and without AF (4% in the diet) for 6 weeks. Changes in body 
weight, blood glucose level, and food intake were measured daily for 42 days. Dietary 
supplementation of AF resulted in a significant decrease of blood glucose level (p < 0.001) 
and body weight (p < 0.001). The level of HbA1c, a better indicator of plasma glucose 
concentration over prolonged periods of time, was also significantly decreased for 6-week 
period (p < 0.001). Dietary treatment of acarbose® (0.04% in diet), a positive control,  
also significantly alleviated the level of blood glucose, HbA1c, and body weight. These 
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results indicate that AF Maillard reaction product improves postprandial hyperglycemia by 
suppressing glucose absorption as well as decreasing HbA1c level. 




Non-insulin dependent diabetes mellitus (NIDDM, type 2 diabetes) is a common disorder of 
glucose and fat metabolism that affects approximately 171 million people worldwide, generating 
immense health care costs [1]. Type 2 diabetes accounts for about 90% to 95% of all diagnosed cases 
of diabetes in adults [2]. Pre-diabetes is a condition in which individuals have blood glucose levels 
higher than normal but not high enough to be classified as diabetes [3]. In the United States, in 2010, 
25.8 million people (10% of American adults) had diabetes and by 2050 this figure is expected to jump 
to 33%, or one-third of all American adults [2]. 
Hyperglycemia is a condition characterized by a rapid rise in blood glucose levels, which is due, 
primarily, to increased hydrolysis of starch by pancreatic α-amylase and α-glucosidases, leading to 
enhanced absorption of glucose in the small intestine. One of the therapeutic approaches for decreasing 
postprandial hyperglycemia is thus to retard absorption of glucose by the inhibition of carbohydrate 
hydrolyzing enzymes, mainly α-amylase and α-glucosidase, in the digestive organs [4]. Therefore, 
inhibition of these enzymes can significantly decrease the postprandial hyperglycemia after a mixed 
carbohydrate diet and can be a key strategy in the control of diabetes mellitus [5]. 
We have previously reported that Amadori compounds can reduce carbohydrate absorption in the 
small intestine by inhibiting carbohydrate hydrolyzing enzymes in both in vitro and in vivo animal 
model [6]. Korean red ginseng has been shown to have various biological effects, including antioxidant 
activity, and anti-diabetic, antitumor and stress relieving effects [7–9]. During steaming and drying 
processes that are necessary for the production of Korean red ginseng, certain components undergo 
non-enzymatic browning reaction, otherwise known as a Maillard reaction. In the early stage of 
Maillard reaction, Amadori compounds such as arginyl-fructosyl-glucose (AFG) and arginyl-fructose 
(AF) are formed through Amadori rearrangement of arginine with glucose or maltose, respectively [10,11]. 
In our previous study, AF was chemically synthesized and the inhibitory activities against rat 
intestinal α-glucosidases and porcine pancreatic α-amylase were investigated in vitro and in animal 
model [6]. We reported that dietary AF reduced postprandial glucose level in Sprague-Dawley (SD) rat 
model via inhibition of carbohydrate hydrolysis enzymes. This was the first report for the potential of 
AF for type 2 diabetes management. However, there is still limited information in the literature about 
the dietary effect of long-term AF supplementation on type 2 diabetes management and particularly on 
hyperglycemia in vivo.  
Therefore, the aim of this study is to investigate the effect of long-term dietary supplementation of 
AF on the type 2 diabetes management using db/db mice, a genetic model for type 2 diabetes. In this 
study, AF was chemically synthesized and administrated for 42 days in db/db mice. The effect of long 
term administration of AF was compared to acarbose and control for fasting glucose levels, HbA1c, 
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total cholesterol and triglyceride contents. Data from the current study provide the potential mechanism 
of action of AF for the management of type 2 diabetes and also help design future clinical trials. 
2. Results and Discussion 
db/db Mice Trial 
The effect of arginyl-fructose (AF) administration was evaluated in db/db mouse model for 42 days 
and compared to the effect of acarbose. After 42 days we observed that the body weight of AF treated 
group was similar to acarbose treatment and significantly lower compared to control (p < 0.001) 
(Figure 1). A significant difference between control and treatments (AF and acarbose) can be identified 
after 14 days of administration (Figure 1). In addition, we observed that the AF and control animals 
had similar levels of food consumption, while food intake was dramatically increased in the acarbose 
group (Figure 2). 
Figure 1. Changes in body weight gains after administration of arginyl-fructose (AF). 
Male db/db mice were free access to a high carbohydrate-diet with AF (4%), acarbose 
(0.04%), and vehicle for 6 weeks. Each point represents mean ± standard deviation (SD). 
(n = 10). Body weight levels were compared between control and treatment groups at each 


















Effects of AF treatment after 42 days on fasting blood glucose, HbA1c, HDL-cholesterol, 
triglyceride content, and cecum weight were also evaluated as shown in Table 1. We observed that 
fasting glucose level was significantly reduced with AF treatment to the level similar to acarbose  
(p < 0.001) (Table 1). The fasting blood glucose level of control group was around 558.6 (mg/dL), 
while the levels of AF and acarbose groups were 264.2 and 223.8 (mg/dL), respectively (Table 1). 
Similarly, the control group had HbA1c levels around 9.8%, while AF and acarbose resulted in 
significantly lower levels (7.1% and 5.1%, respectively) (Table 1). Triglyceride levels of AF and 
acarbose were found to be similar amounts (Table 1). HDL-cholesterol was significantly increased 
only with AF supplementation (157.1 mg/dL), while control and acarbose had similar HDL-cholesterol 
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levels (121.4 and 101.6 mg/dL, respectively) (Table 1). Finally, the cecum weight was determined at 
the end of the experiment and acarbose treatment group had the largest cecum (1.60 g), followed by 
control (0.28 g), while AF treatment had the smallest cecum weight (0.27 g) (Table 1). 
Figure 2. Changes in food intake after administration of AF. Male db/db mice were free 
access to a high carbohydrate-diet with AF (4%), acarbose (0.04%) or vehicle for 6 weeks. 
Each point represents mean ± SD (n = 10). Food intake levels were compared between 




















Table 1. Effect of AF and acarbose treatment on various parameters in db/db mice. 
Parameters 
db/db mice 
Control Acarbose AF 
Glucose (mg/dL) 558.6 ± 57.9 223.8 ± 77.0 *** 264.2 ± 21.5 *** 
HbA1c (%) 9.8 ± 1.0 5.1 ± 0.80 *** 7.1 ± 0.6 *** 
HDL-Cholesterol (mg/dL) 121.4 ± 25.6 101.6 ± 18.8 157.1 ± 4.5 ** 
Triglyceride (mg/dL) 217.0 ± 22.7 129.2 ± 18.3 *** 130.4 ± 26.9 *** 
Cecum (g) 0.28 ± 0.09 1.60 ± 0.40 *** 0.27 ± 0.07 
Each point represents mean ± SD (n = 10). All parameter were compared between control and treatment 
groups at 42 days by unpaired Student’s t-test (** p < 0.01; and *** p < 0.001).  
We observed that the body weight, fasting glucose levels, and HbA1c levels of AF treated group 
were similar to acarbose treatment and significantly lower compared to control (Figure 1, Table 1). 
The above findings suggest that AF is preventing the progression of obesity and diabetes due to 
carbohydrate-rich diet in db/db mice, in similar manner to the known α-glucosidase inhibitor, acarbose 
(Figure 1, Table 1), without having the side-effect of excessive α-amylase inhibition observed with the 
acarbose treatment that results to significantly increased cecum weight (Table 1). The major side effect 
of acarbose administration is flatulence and diarrhea resulting from the excessive inhibition of starch 
breakdown. This inhibition of pancreatic α-amylase by acarbose may induce major adverse effects 
such as abdominal distention, flatulence, meteorism, and diarrhea a consequence of undigested 
carbohydrates entering the colon where they are used as nutrients for bacterial growth [12,13]. The 
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differences in cecum weight and volume among the control, acarbose, and AF groups are shown in 
Table 1. Acarbose administration resulted in a 5-fold increase in the weight and volume of the cecum 
compared with the control and AF, which is consistent with a previous study [12,13]. Based strictly on 
cecum observations, we can suspect that AF supplementation results to weak inhibition of α-amylase 
that results to slight increase of cecum weight when compared to the control (Table 1). 
Our observations suggest that AF supplementation in db/db mice along with high starch diet results 
to fasting blood glucose level, HbA1c, and total weight reductions to a similar level as acarbose,  
α-glucosidase inhibitor on the market (Figure 1, Table 1). AF and acarbose administration has similar 
trend and effect on fasting blood glucose levels, HbA1c, and body weight (Figure 1, Table 1). HbA1c 
is a scientifically advanced test that measures the average blood glucose level over the entire previous 
12 weeks period and can accurately evaluate the long-term blood sugar management [14]. Studies have 
found that HbA1c is an excellent marker of metabolic wellness, with reduced levels being associated 
with enhanced health. Every unit decrease in HbA1c (e.g., from 6 to 5) has been found to be associated 
with, for example, significant reductions in heart attacks (−14%), peripheral blood vessel disease 
(−43%), death due to diabetic complications (−21%), and cataracts (−19%) [14]. Interestingly, the 
control group had HbA1c levels around 9.8%, while AF and acarbose resulted in significantly lower 
levels (7.1% and 5.1%, respectively) in this study (Table 1). 
3. Experimental Section 
3.1. Materials 
Corn starch, casein, vitamin mix, mineral mix, calcium phosphate and sodium chloride were 
purchased from Raon Bio (Yongin, Korea). Total cholesterol and total triglyceride kits were purchased 
from Stanbio laboratory (LiquiColor® Test series, Boerne, TX, USA). Blood glucose tester was 
purchased from Caresens (I-SENS, Anyang, Korea) and HbA1c analyzer was purchase from Infopia Inc. 
(Clover A1c™, Anyang, Korea). Standard arginyl-fructose was purchased from Proteinworks Co. 
(Daejeon, Korea). Unless noted, all chemicals were purchased from Sigma-Aldrich Co. (St. Louis, 
MO, USA). 
3.2. Animal and Study Design 
Five-week-old male C57BL/KsJ-db/db (db/db) mice were purchased from Joongang Experimental 
Animal Co. (Seoul, Korea) and fed a Pico 5053 diet (Oriental Bio. Co., Seongnam, Korea) for 1 week. 
The animals were housed in individual cages in a room with a 12 h light/dark cycle (lights on from 
06:00 h) with 50% ± 7% relative humidity. In this study, ten db/db mice were used for each group.  
All mice were adapted to a meal-feeding schedule of free access to Pico 5053 diet with or without 
samples for 6 weeks (Table 2). The experimental protocols were approved by the Institutional Animal 
Care and Use Committee (IACUC) of the Hannam University (Approval number: HNU2012-003). The 
mice had free access to tap water throughout the experimental period. The mice were anesthetized with 
pentobarbital and killed, and blood was collected. The cecum weight was determined using analytical 
balance after biopsy. 
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Table 2. Composition of diets (g/kg). 
High carbohydrate diets Control AF Acarbose 
Corn Starch 661 621 660.6 
Casein 226 226 226 
Soybean oil 60 60 60 
Vitamin mix (1) 31 31 31 
Mineral mix (2) 9 9 9 
Calcium phospahte 10 10 10 
Sodium chloride 3 3 3 
Sample (AF) – 40 – 
Acarbose – – 0.4 
(1) Vitamin mixture: AIN-93VX; (2) Mineral mixture: AIN-93G. 
3.3. Blood Analysis 
The blood glucose level was measured with a glucose analyzer (CaresensII, I-SENS Inc., Anyang, 
Korea) using the glucose oxidase method, and the plasma total cholesterol and total glyceride 
concentration was measured using a kit (Liquicolor® test series, Stanbio Laboratory, Boerne, TX, 
USA). The concentration of HbA1c was measured using Nycocard reader (Clover A1c™, Infopia Inc., 
Anyang, Korea). 
3.4. Statistical Analysis 
All data are presented as mean ± SD. Statistical analyses were carried out using the statistical 
package SPSS 10 (Statistical Package for Social Science, SPSS Inc., Chicago, IL, USA) program and 
significance of each group was verified with the analysis of One-way ANOVA followed by the 
Student’s t-test for comparison of means. 
4. Conclusions 
One of the therapeutic approaches for decreasing postprandial hyperglycemia is to retard absorption 
of glucose by the inhibition of carbohydrate hydrolyzing enzymes, α-amylase and α-glucosidase, in the 
digestive organs [7,8]. Therefore, inhibition of these enzymes can significantly decrease the postprandial 
hyperglycemia after a mixed carbohydrate diet and can be a key strategy in the control of diabetes 
mellitus [9–17]. Due to the high enrichment of arginine in crude ginseng, AF is the major Amadori 
compounds formed by the reaction of maltose, arginine and glucoserespectively during the steaming 
and heat-drying processes of Korean red ginseng preparation. Compared to the ginsenosides content 
(0.5%~1.1% in Korean red ginseng) [18,19], commercial red ginseng could have significant levels of 
AF and AFG, ranging from 0.4% to 2.5% and 0.3% to 2.6%, respectively [6]. Therefore, with the 
increasing recognition of the various therapeutic effects of Korean red ginseng, application of AF as 
health food or alternative medicine needs to be thoroughly evaluated. In this manuscript we report that 
AF can effectively manage the fasting blood glucose and HbA1c levels in db/db mice, in a similar 
manner to acarbose. Here, we show in an animal model that the mechanism involves inhibition of 
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carbohydrate hydrolysis enzymes. Our findings provide evidence for the potential application of AF 
for the management of type 2 diabetes, that need to be further confirmed in a clinical level. 
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